RTW Investments LP recently announced the acquisition of new stake in Immunocore Holdings plc ADR (NASDAQ:IMCR). The institutional investor has increased its shareholding in the Healthcare company by 1.11% to 6.1 million shares with purchase of 66754.0 shares. This fresh investment now brings its stake to 12.68% valued currently at $416.51 million. In addition, Wellington Management Co. LLP raised its holdings by 0.22 million to 3.91 million shares. And T. Rowe Price Associates, Inc. has lifted its position by 4.04% or 97864.0 shares – to 2.52 million shares.
With over 0.27 million Immunocore Holdings plc ADR (IMCR) shares trading Friday and a closing price of $71.56 on the day, the dollar volume was approximately $19.66 million. The shares have shown a positive half year performance of 12.87% and its price on 01/12/24 lost nearly -3.02%. Currently, there are 49.44M common shares owned by the public and among those 48.38M shares have been available to trade.
The top 3 mutual fund holders in Immunocore Holdings plc ADR are Vanguard Health Care Fund, T Rowe Price Health Sciences Fund, and Polar Capital Funds Plc – Biotech. Vanguard Health Care Fund owns 2.09 million shares of the company’s stock, all valued at over $142.49 million. T Rowe Price Health Sciences Fund bought 70411.0 shares to see its total holdings expand to 1.73 million shares valued at over $118.18 million and representing 3.60% of the shares outstanding. Polar Capital Funds Plc – Biotech bought 0.18 million shares to bring its total holdings to over 0.53 million shares at a value of $36.21 million. Polar Capital Funds Plc – Biotech now owns shares totaling to 1.10% of the shares outstanding.
Shares of Immunocore Holdings plc ADR (NASDAQ: IMCR) opened at $73.02, down -$0.77 from a prior closing price of $73.79. The company’s stock has a 5-day price change of 7.53% and 48.16% over the past three months. IMCR shares are trading 4.74% year to date (YTD), with the 12-month market performance up to 25.74% higher. It has a 12-month low price of $42.21 and touched a high of $74.75 over the same period. IMCR has an average intraday trading volume of 358.38K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 6.42%, 25.75%, and 26.64% respectively.
Institutional ownership of Immunocore Holdings plc ADR (NASDAQ: IMCR) shares accounts for 72.79% of the company’s 49.44M shares outstanding. Mutual fund holders own 21.85%, while other institutional holders and individual stakeholders account for 53.08% and — respectively.
It has a market capitalization of $3.54B and a beta (3y monthly) value of 0.96. The earnings-per-share (ttm) stands at -$1.35. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.28% over the week and 5.53% over the month.
Analysts forecast that Immunocore Holdings plc ADR (IMCR) will achieve an EPS of -$0.28 for the current quarter, -$0.32 for the next quarter and -$1.64 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.54 while analysts give the company a high EPS estimate of -$0.06. Comparatively, EPS for the current quarter was -$0.68 a year ago. Earnings per share for the fiscal year are expected to increase by 8.99%, and -55.71% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 17 brokerage firm advisors rate Immunocore Holdings plc ADR (IMCR) as a “Strong Buy” at a consensus score of 1.29. Specifically, 13 Wall Street analysts polled rate the stock as a buy, while 1 of the 17 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the IMCR, a number of firms have released research notes about the stock. JP Morgan stated their Overweight rating for the stock in a research note on November 20, 2023, with the firm’s price target at $60.
